116
Participants
Start Date
December 31, 2014
Primary Completion Date
January 30, 2017
Study Completion Date
April 10, 2018
Standard dose cytarabine for induction
100 mg/m2/day Days 1-7
SGN-CD33A
Given intravenously Day 1 or Days 1 and 4 of each cycle
Daunorubicin
60 mg/m2/day Days 1-3
High dose cytarabine for consolidation
3g/m2 on Days 1, 3, and 5 of each cycle
Sarah Cannon Research Institute, Nashville
University of Alabama at Birmingham, Birmingham
James Cancer Hospital / Ohio State University, Columbus
Cleveland Clinic, The, Cleveland
Karmanos Cancer Institute / Wayne State University, Detroit
Cardinal Bernardin Cancer Center / Loyola University Medical Center, Maywood
Charles A. Sammons Cancer Center / Baylor University Medical Center, Dallas
Colorado Blood Cancer Institute, Denver
City of Hope National Medical Center, Duarte
Massachusetts General Hospital, Boston
Hackensack University Medical Center, Hackensack
MD Anderson Cancer Center / University of Texas, Houston
Fred Hutchinson Cancer Research Center, Seattle
Seagen Inc.
INDUSTRY